JAGUAR HEALTH, INC. Capital Expenditures Incurred but Not yet Paid
JAGUAR HEALTH, INC. (JAGX) reported Capital Expenditures Incurred but Not yet Paid of $6.00 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2022-05-10
- JAGUAR HEALTH, INC. capital expenditures incurred but not yet paid for the quarter ending 2021-03-31 was $6.00K.
- JAGUAR HEALTH, INC. capital expenditures incurred but not yet paid for the quarter ending 2016-06-30 was -$6.31K.
- JAGUAR HEALTH, INC. capital expenditures incurred but not yet paid for the quarter ending 2016-03-31 was $12.25K.
- JAGUAR HEALTH, INC. capital expenditures incurred but not yet paid for the quarter ending 2014-12-31 was $0.00.
- JAGUAR HEALTH, INC. capital expenditures incurred but not yet paid for fiscal 2014 was $817.37K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2021-03-31 | $6.00K 10-Q · filed 2022-05-10 | |||
| 2016-06-30 | -$6.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $5.94K 10-Q · filed 2016-08-15 | ||
| 2016-03-31 | $12.25K 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-29 | $0.00 derived: sum of 2 quarters · filed 2016-03-29 | $0.00 derived: sum of 3 quarters · filed 2016-03-29 | $817.37K 10-K · filed 2016-03-29 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $0.00 derived: sum of 2 quarters · filed 2015-11-13 | $817.37K 10-Q · filed 2015-11-13 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $817.37K 10-Q · filed 2015-08-13 | ||
| 2014-03-31 | $817.37K 10-Q · filed 2015-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |